Inventor · disambiguated record
Brian Lannutti
Also filed as: LANNUTTI BRIAN · LANNUTTI BRIAN J
18 granted patents·43 pending applications·70 citations·filing 2010–2024
93Inventor score
Files withACERTA PHARMA BV34GILEAD CALISTOGA LLC8VELOSBIO INC7ONCTERNAL THERAPEUTICS INC4GILEAD SCIENCES INC3
Top patents by PatentIndex Score
61 records- 0196US11771696B2Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitorACERTA PHARMA BV·Filed 2021·Granted Oct 3, 2023·5 cites·12 claims
- 0295US9949971B2Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitorACERTA PHARMA BV·Filed 2015·Granted Apr 24, 2018·11 cites·26 claims
- 0394US11654143B2Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitorACERTA PHARMA BV·Filed 2021·Granted May 23, 2023·3 cites·21 claims
- 0493US10272083B2Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitorACERTA PHARMA BV·Filed 2015·Granted Apr 30, 2019·14 cites·20 claims
- 0592US11285132B2Uses of indolinone compoundsONCTERNAL THERAPEUTICS INC·Filed 2020·Granted Mar 29, 2022·3 cites·8 claims
- 0691US11090302B2Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitorACERTA PHARMA BV·Filed 2019·Granted Aug 17, 2021·4 cites·10 claims
- 0790US12161626B2Uses of indolinone compoundsONCTERNAL THERAPEUTICS INC·Filed 2022·Granted Dec 10, 2024·1 cites·20 claims
- 0889US10646470B2Uses of indolinone compoundsONCTERNAL THERAPEUTICS INC·Filed 2018·Granted May 12, 2020·3 cites·8 claims
- 0988US10335496B2ROR1 antibody immunoconjugatesVELOSBIO INC·Filed 2018·Granted Jul 2, 2019·9 cites·84 claims
- 1088US10159660B2Uses of indolinone compoundsONCTERNAL THERAPEUTICS INC·Filed 2017·Granted Dec 25, 2018·6 cites·8 claims
- 1186US12263164B2Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitorACERTA PHARMA BV·Filed 2023·Granted Apr 1, 2025·0 cites·18 claims
- 1284US10328080B2Therapeutic combination of PI3K inhibitor and a BTK inhibitorACERTA PHARMA BV·Filed 2014·Granted Jun 25, 2019·6 cites·15 claims
- 1384US2024216380A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2023·Application pending·0 cites
- 1482US2025090525A1Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis RateACERTA PHARMA BV·Filed 2024·Application pending·0 cites
- 1580US11166951B2Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitorACERTA PHARMA BV·Filed 2018·Granted Nov 9, 2021·2 cites·18 claims
- 1674US9492449B2Therapies for hematologic malignanciesGALLATIN W MICHAEL·Filed 2012·Granted Nov 15, 2016·2 cites·16 claims
- 1773US2021346382A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2021·Application pending·0 cites
- 1869US2021322408A1Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis RateACERTA PHARMA BV·Filed 2021·Application pending·0 cites
- 1969US2019314369A1Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis RateACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 2068USRE50631EROR1 antibody immunoconjugatesVELOSBIO INC·Filed 2021·Granted Oct 14, 2025·0 cites·99 claims
- 2168US11154554B2Therapeutic combinations of a MEK inhibitor and a BTK inhibitorACERTA PHARMA BV·Filed 2019·Granted Oct 26, 2021·0 cites·4 claims
- 2268US2022133901A1Ror1 antibody immunoconjugatesVELOSBIO INC·Filed 2021·Application pending·0 cites
- 2368US2020368243A1Therapies for hematologic malignanciesGILEAD CALISTOGA LLC·Filed 2020·Application pending·0 cites
- 2467US2024197742A1Therapeutic Combinations of a CD19 Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2023·Application pending·0 cites
- 2564US2019381044A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 2663US8546409B2Methods of treatment for solid tumorsPURI KAMAL D·Filed 2010·Granted Oct 1, 2013·1 cites·25 claims
- 2762US2015148345A1Therapies for treating myeloproliferative disordersGILEAD SCIENCES INC·Filed 2014·Application pending·0 cites
- 2862US2018369244A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 2961US2019083498A1Therapies for hematologic malignanciesGILEAD CALISTOGA LLC·Filed 2018·Application pending·0 cites
- 3061US2019209591A1Therapeutic Combinations of a Proteasome Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 3160US2020030454A1ROR1 Antibody ImmunoconjugatesVELOSBIO INC·Filed 2019·Application pending·0 cites
- 3259US10154998B2Therapies for hematologic malignanciesGILEAD CALISTOGA LLC·Filed 2016·Granted Dec 18, 2018·0 cites·16 claims
- 3359US2018250400A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK4/6 InhibitorACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 3458US2018207154A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor and/or a JAK-2 InhibitorACERTA PHARMA BV·Filed 2018·Application pending·0 cites
- 3557US2020069668A1Therapeutic Combinations of an IRAK4 Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 3656US2017231986A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 InhibitorACERTA PHARMA BV·Filed 2015·Application pending·0 cites
- 3756US2020069796A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 InhibitorACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 3855US2017035881A1Therapeutic Combinations of an IRAK4 Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2016·Application pending·0 cites
- 3955US2019008869A1Therapeutic Combinations of an Antifolate and a BTK InhibitorACERTA PHARMA BV·Filed 2017·Application pending·0 cites
- 4054US2017143712A1Methods of Treating Cancers, Immune and Autoimmune Diseases, and Inflammatory Diseases Based on BTK Occupancy and BTK Resynthesis RateACERTA PHARMA BV·Filed 2017·Application pending·0 cites
- 4154US2017231995A1BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor MicroenvironmentACERTA PHARMA BV·Filed 2015·Application pending·0 cites
- 4254US2017071962A1Therapeutic Combinations of a Proteasome Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2016·Application pending·0 cites
- 4354US2019008859A1Therapeutic Combinations of a MEK Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2016·Application pending·0 cites
- 4453US2019374543A1Therapeutic Combinations of an Antifolate and a BTK InhibitorACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 4552US2019358235A1Therapeutic Combination of a PI3K Inhibitor and a BTK InhibitorACERTA PHARMA BV·Filed 2019·Application pending·0 cites
- 4651US2016279135A1Therapies for treating myeloproliferative disordersGILEAD SCIENCES INC·Filed 2016·Application pending·0 cites
- 4751US2017224819A1Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 InhibitorACERTA PHARMA BV·Filed 2015·Application pending·0 cites
- 4849US2023293712A1Novel ror1 antibody immunoconjugatesVELOSBIO INC·Filed 2021·Application pending·0 cites
- 4948US2013143902A1Compositions and methods of treating a proliferative disease with a quinazolinone derivativeGILEAD CALISTOGA LLC·Filed 2012·Application pending·0 cites
- 5048US2013344138A1Methods of treatment for solid tumorsGILEAD CALISTOGA LLC·Filed 2013·Application pending·0 cites
Showing the top 50 of 61 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Brian Lannutti files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →